title: The role of kinesiotaping combined with botulinum toxin to reduce plantar flexors spasticity after stroke.
abstract: OBJECTIVE
  To evaluate the effect of kinesiotaping as an adjuvant therapy to botulinum toxin A (BTX-A) injection in lower extremity spasticity.
  
  
  METHODS
  This is a single-center, randomized, and double-blind study. Twenty hemiplegic patients with spastic equinus foot were enrolled into the study and randomized into 2 groups. The first group (n=10) received BTX-A injection and kinesiotaping, and the second group (n=10) received BTX-A injection and sham-taping. Clinical assessment was done before injection and at 2 weeks and 1, 3, and 6 months. Outcome measures were modified Ashworth scale (MAS), passive ankle dorsiflexion, gait velocity, and step length.
  
  
  RESULTS
  Improvement was recorded in both kinesiotaping and sham groups for all outcome variables. No significant difference was found between groups other than passive range of motion (ROM), which was found to have increased more in the kinesiotaping group at 2 weeks.
  
  
  CONCLUSIONS
  There is no clear benefit in adjuvant kinesiotaping application with botulinum toxin for correction of spastic equinus in stroke.
authors.affiliation: Department of Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey.
authors.forename: Evrim
authors.initials: E
authors.lastname: Karadag-Saygi
authors.forename: Koza
authors.initials: K
authors.lastname: Cubukcu-Aydoseli
authors.forename: Nilufer
authors.initials: N
authors.lastname: Kablan
authors.forename: Demet
authors.initials: D
authors.lastname: Ofluoglu
mesh_terms: D000368:Aged; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D004185:Disability Evaluation; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006429:Hemiplegia / Q000188:drug therapy* / Q000209:etiology / Q000534:rehabilitation*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D026741:Physical Therapy Modalities; D011597:Psychomotor Performance / Q000502:physiology*; D020521:Stroke / Q000150:complications; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A